Table 3.
Patients who received SpaceOAR prior to any radiation therapy compared to those who received SpaceOAR on the day of brachytherapy seed implant
| Continuous variable | SpaceOAR before XRT (n = 83) |
SpaceOAR at brachy (n = 91) |
p-value† | Total SpaceOAR pts. (n = 174) |
|||
|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | ||
| TRUS prostate volume (cm3) | 22.7 | (6.3) | 23.5 | (5.7) | 0.366 | 23.1 | (6.0) |
| Planning target volume, PTV (cm3) | 48.0 | (10.5) | 48.3 | (9.6) | 0.828 | 48.2 | (10.0) |
| Post-implant CT volume (cm3) | 65.1 | (12.6) | 66.7 | (11.3) | 0.389 | 65.9 | (11.9) |
| PTV D90 (%) | 123.3 | (10.7) | 119.1 | (9.0) | 0.005 | 121.1 | (10.0) |
| PTV V100 (%) | 98.0 | (1.6) | 97.4 | (1.9) | 0.024 | 97.7 | (1.8) |
| PTV V150 (%) | 73.4 | (7.1) | 70.7 | (7.2) | 0.012 | 72.0 | (7.3) |
| PTV V200 (%) | 46.1 | (7.1) | 43.2 | (6.5) | 0.005 | 44.6 | (6.9) |
| Prostatic urethral dose (%) | 115.4 | (14.1) | 108.5 | (8.5) | < 0.001 | 111.8 | (12.0) |
| Prostatic urethral dose, max. (%) | 132.8 | (22.1) | 122.2 | (14.0) | < 0.001 | 127.2 | (19.0) |
| Bulbomembranous dose (Gy) | 34.9 | (12.7) | 34.3 | (15.8) | 0.772 | 34.6 | (14.3) |
| Rectal dose (%) | 23.8 | (8.5) | 21.8 | (8.5) | 0.122 | 22.8 | (8.5) |
| Rectal dose, max. (%) | 33.9 | (12.5) | 31.4 | (11.5) | 0.173 | 32.6 | (12.0) |
| Rectum V110 (cm3) | 0.002 | (0.016) | 0.014 | (0.118) | 0.349 | 0.008 | (0.086) |
| Rectal wall V50 (cm3) | 0.596 | (0.801) | 0.571 | (0.754) | 0.840 | 0.583 | (0.775) |
†
Two sample t-test, p-values ≤ 0.5 in bold